Comparative Pharmacology
Head-to-head clinical analysis: DILACOR XR versus VERELAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DILACOR XR versus VERELAN.
DILACOR XR vs VERELAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diltiazem inhibits calcium ion influx across cardiac and vascular smooth muscle cells, resulting in dilation of coronary and systemic arteries, decreased myocardial contractility, and reduced sinoatrial and atrioventricular conduction velocity.
Verapamil inhibits calcium ion influx across cardiac and smooth muscle cells, blocking L-type calcium channels, leading to vasodilation and negative chronotropic, dromotropic, and inotropic effects.
180 to 240 mg orally once daily, administered on an empty stomach; maximum dose 480 mg once daily.
Hypertension: 120-240 mg ER orally once daily; maximum 480 mg/day. Angina: 80-120 mg IR orally three times daily; ER 180-360 mg once daily.
None Documented
None Documented
Terminal half-life: 6-12 hours (prolonged in elderly, hepatic impairment, or with CYP3A4 inhibitors)
Terminal elimination half-life is 2.8 to 7.4 hours in healthy adults, prolonged in hepatic impairment or elderly (up to 12 hours).
Renal (70% as metabolites, 3-4% as unchanged drug); biliary/fecal (25-30%)
Renal excretion accounts for approximately 70% of elimination, with 3-4% as unchanged drug. Fecal elimination accounts for about 25%, predominantly via biliary secretion.
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker